NK-92最初來源于NK淋巴瘤患者的血液，該細(xì)胞系不表達(dá)KIRs。 不知為何，大部分患者不排斥這種細(xì)胞。NantKwest通過裝上一個(gè)CAR對(duì)NK92進(jìn)行了改造，在鉻釋放試驗(yàn)中，它殺死K562細(xì)胞和Daudi細(xì)胞，可有效的用于血液中的白血病的體外免疫。

組織來源：血液

形態(tài)：淋巴樣懸浮生長，多細(xì)胞聚集

培養(yǎng)基配方:

α-MEM（MD0800）+2 mM L-谷氨酰胺(SD0007) +1.5 g/L sodium bicarbonate+ 0.2 mM 肌醇(SD0014)+0.1 mM 2-巰基乙醇(SD0031)+0.02 M 葉酸(SD0016)+100-200 U/ml IL-2+of 12.5% 馬血清(SD0300) + 12.5% FBS(SD0200)+1%GA(SD0038)

完全培養(yǎng)基：MEM-α完全培養(yǎng)基 （MD0806）

氣相：空氣，95%；二氧化碳，5%。 溫度：37℃。

完全凍存液：免程序降溫細(xì)胞凍存液（低血清）(SD0001)

聲明：產(chǎn)品僅科研使用。

PubMed=8152260

Gong J.-H., Maki G., Klingemann H.-G.

Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.

Leukemia 8:652-658(1994)

PubMed=9118301

Klingemann H.-G., Wong E., Maki G.

A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.

Biol. Blood Marrow Transplant. 2:68-75(1996)

PubMed=10365666; DOI=10.1089/10430349950018030

Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G.

Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.

Hum. Gene Ther. 10:1359-1373(1999)

PubMed=10803505; DOI=10.1038/sj.leu.2401778

Drexler H.G., Matsuo Y.

Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.

Leukemia 14:777-782(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11454312; DOI=10.1089/152581601750288975

Maki G., Klingemann H.-G., Martinson J.A., Tam Y.K.

Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.

J. Hematother. Stem Cell Res. 10:369-383(2001)

PubMed=12850795; DOI=10.1080/14653240310001523

Tam Y.K., Martinson J.A., Doligosa K., Klingemann H.-G.

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.

Cytotherapy 5:259-272(2003)

PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392

Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner L.M.

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

J. Immunol. 180:6392-6401(2008)

PubMed=19194464; DOI=10.1038/leu.2009.3

Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H., Klinkebiel D., Christman J.K., Patel K., Cao K., Shen L., Dybkaer K., Tsui I.F.L., Ali H., Shimizu N., Au W.Y., Lam W.L., Chan W.C.

Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.

Leukemia 23:1139-1151(2009)

PubMed=20454443; DOI=10.1155/2010/904767

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

J. Biomed. Biotechnol. 2010:904767-904767(2010)

PubMed=21052088; DOI=10.1038/leu.2010.255

Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.Y., Srivastava G., Greiner T.C., Kucuk C., Deffenbacher K., Vose J., Smith L., Au W.Y., Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H., Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.C.

Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.

Leukemia 25:348-358(2011)

PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010

Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S., Zocher M.

Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.

Mol. Immunol. 48:1512-1517(2011)

PubMed=25586472; DOI=10.1038/ncomms7025

Kucuk C., Jiang B., Hu X., Zhang W., Chan J.K.C., Xiao W., Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A., Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W., Cornish A., Gong Q., Yang Q., Sun H., d'Amore F., Leppa S., Liu W., Fu K., de Leval L., McKeithan T., Chan W.C.

Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.

Nat. Commun. 6:6025-6025(2015)

PubMed=26559813; DOI=10.1007/s00262-015-1761-x

Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S., Klingemann H.-G., Tonn T.

NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Cancer Immunol. Immunother. 65:485-492(2016)

PubMed=31126350; DOI=10.1186/s40425-019-0612-2

Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C., Eom K.-S., Kim S.W.

Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.

J. Immunother. Cancer 7:138-138(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)